Geninus (389030) has announced that a research paper co-authored by CEO Woong-Yang Park has been published in Cell, a leading life sciences journal with an impact factor of 45.5. The study analyzes immune cells at the single-cell level from populations in Singapore, Japan, Thailand, and India, providing insights into the immune characteristics of Asian ethnic groups.
Immune traits play a crucial role in disease progression and treatment response, particularly in cancer. The characteristics of immune cells within tumors can influence the effectiveness of immunotherapy and antibody-drug conjugates (ADC), making immune cell analysis essential for drug development. Geninus’ drug development solution, Space Insight, is a software tool that maps the distribution and state of immune cells within tumors, providing valuable data for pharmaceutical companies developing ADC therapies. According to medical experts, Geninus is integrating genomic data with AI technology to support cancer drug development and strengthen its global market competitiveness. The research published in Cell is considered a significant milestone in cancer treatment innovation. CEO Park stated that the publication of the Cell paper is a major achievement in demonstrating Geninus’ technological capabilities to global pharmaceutical companies. He emphasized that growing interest from ADC developers could lead to improved drug development success rates and innovative treatments for cancer patients.<\/p>\r\n